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Abstract
Objective—The FASTER trial compared 1st and 2nd trimester screening methods for aneuploidy.
We examined relationships between maternal serum markers and common congenital anomalies in
the pediatric outcome data set of 36,837 subjects.
Methods—We used nested case control studies, with cases defined by the most common
anomalies in our follow-up database, and up to four controls matched by enrollment site, maternal
age and race, enrollment gestational age, and infant gender. Serum markers were dichotomized to
≥ 2 or < 0.5 multiples of the median (MoM). Odds ratios and 95% confidence intervals (C.I.) were
estimated.
Results—Statistically significant (p < 0.05) associations were found between inhibin A ≥ 2
MoM and fetal multicystic dysplastic kidney (MCDK) (odds ratio (OR) =27.5, 95% C.I.:
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2.8-267.7) and 2-vessel cord (OR=4.22, 95% CI:1.6-10.9), hCG of ≥ 2 MoM with MCDK
(OR=19.56, 95% CI: 1.9-196.2) and hydrocele (OR=2.48, 95% CI: 1.3-4.6), and PAPPA ≥ 2.0
MoM with hydrocele (OR=1.88, 95% CI:1.1-3.3).
Conclusion—In this large prospective study, significant associations were found between
several maternal serum markers and congenital anomalies. This suggests potential additional
benefits to screening programs that are primarily designed to detect aneuploidy.
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INTRODUCTION
Noninvasive prenatal diagnosis using maternal serum markers initially focused on detection
of open neural tube defects and subsequently on detection of aneuploidies such as trisomies
21 and 18. More recently, associations between abnormal levels of maternal serum markers
and single gene disorders, such as Smith-Lemli-Opitz and Cornelia de Lange, have been
found (Canick et al., 1997; Aitken et al., 1999; Palomaki et al., 2002; Craig et al., 2006).
Few studies to date have examined the possibility of using maternal serum screening results
to detect common congenital anomalies or single gene disorders other than those that are
mentioned above (Celentano et al., 2005).
The objective of this study was to assess the association between abnormal levels of
maternal serum markers and specific malformations and/or groups of single gene disorders
in the newborn using data from the FASTER trial.
METHODS
Data source description
The FASTER (First and Second Trimester Evaluation of Risk) trial was an NIHfunded
multicenter study, designed to compare first and second trimester methods of screening for
aneuploidy in singleton pregnancies (Malone et al., 2005a). The study included over 38,033
pregnant women enrolled in 15 clinical centers across the United States. It has been
described in detail and reported elsewhere (Malone et al., 2005a). First trimester screening
included standardized sonographic measurement of the nuchal translucency (NT), maternal
serum free beta subunit of human chorionic gonadotropin (fβhCG), and serum pregnancy
associated plasma protein A (PAPP-A) levels. Second trimester screening included maternal
serum alpha-fetoprotein (AFP), total human chorionic gonadotropin (hCG), unconjugated
estriol (uE3), and inhibin A levels. A maternal screening result was considered “positive” if
the risk of Down syndrome was calculated to be 1/150 during the first trimester or 1/300 in
the second trimester. The FASTER trial study design also included comprehensive
pregnancy and neonatal outcome information, which were incorporated into the study
database.
Study Subjects
The analytic sample for the present study included all participants in the FASTER study
with pediatric outcome data available (n=36,837, 97% ascertainment). Pregnant women
whose fetuses were initially noted to have cystic hygroma on a first trimester sonographic
examination were excluded; their outcome data have been reported separately (Malone et
al., 2005b). Pregnant women carrying karyotype-confirmed aneuploid fetuses were also
excluded from the present study.
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Research coordinators at each clinical site recorded outcome information on study subjects
using a computerized tracking system designed specifically for the FASTER study to
maximize protocol compliance and minimize loss to follow-up. In all cases in which a
possible fetal or neonatal medical problem was suspected, copies of the fetal and pediatric
medical records were obtained and reviewed by a single neonatal nurse (BLM) and a
pediatric geneticist (DWB). In addition, medical records from all cases with a positive
FASTER screening result and a 10% random sample of all enrolled subjects were reviewed.
All structural and functional pediatric abnormalities were entered into a database, which was
then cleaned to consolidate terminology and eliminate redundancy. These results were
reviewed and categorized by anomaly or single gene disorder.
Case-Control Sets
Nine primary outcomes, including the five most commonly observed congenital anomalies
and the four single gene disorder groups observed most commonly in the FASTER trial
outcome study infants, were analyzed separately. Because each of the outcomes occurred
infrequently, we used nested case control studies to efficiently control for key confounding
factors. “Cases” were pregnant women carrying a fetus subsequently confirmed to have an
anomaly or single gene disorder. Up to four unaffected controls for each case were derived
from the FASTER cohort, selected for each outcome considered separately, and matched to
cases by enrollment site, maternal age (or age of the egg if an egg donor was used),
gestational age at enrollment, maternal race, and gender of the infant.
Statistical Analysis
Descriptive statistics were generated on all participants in the study sample (i.e., the full
cohort from which cases and controls were drawn), including means and standard deviations
for continuous variables and relative frequencies for categorical variables. To facilitate
interpretation of associations between serum and ultrasound markers and anomalies, each
serum and ultrasound marker was dichotomized following previous studies reporting
relationships between markers and adverse pregnancy outcomes (Dugoff et al., 2005). Some
markers were hypothesized to be positively associated with outcomes while others were
hypothesized to be negatively associated with outcomes. Two parameterizations of each
marker were evaluated. Specifically, markers were first dichotomized to compare values of
2 multiples of the median (MoMs) or greater with values less than 2 MoMs, and also
dichotomized to compare values of 0.5 MoMs or less with values equal to or exceeding 0.5
MoMs. Crude odds ratios and 95% confidence intervals were estimated to qualify the
associations between each marker and each pediatric outcome using logistic regression
analysis. Due to the small number of cases we were unable to adjust for other potential
confounders. All analyses were performed in SAS Version 9.1 (SAS Institute, Cary, NC).
Results were considered to be statistically significant if the p value was less than 0.05.
RESULTS
A description of the sample of women with non-aneuploid fetuses and complete pediatric
outcome data is shown in Table 1. Women were on average 30 years of age at enrollment
into the FASTER trial, nearly 80% were married, and approximately 5% and 2% reported
using tobacco and alcohol during pregnancy, respectively. More than half had a previous
live birth, and over 26% had a prior history of miscarriage. Approximately 5% of enrolled
subjects had a pregnancy that was conceived using assisted reproductive technology.
The numbers of observed cases and matched controls for each congenital anomaly and
single gene disorder are shown in Table 2. Table 3a shows the odds ratios (OR) and 95%
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confidence intervals reflecting the association between serum markers and each of the most
commonly observed congenital anomalies. hCG ≥ 2 MoMs was statistically significantly
associated with hydrocele (OR=2.48, 95% confidence interval (CI): 1.3-4.6) and multicystic
dysplastic kidney (OR=19.56, 95% CI: 1.9-196.2). Inhibin ≥ 2 MoMs was significantly
associated with two-vessel cord (OR=4.22, 95% CI: 1.6-10.9) and multicystic dysplastic
kidney (OR=27.5, 95% CI: 2.8-267.6). Note that the category multicystic dysplastic kidney
included both unilateral and bilateral cases. PAPP-A ≥ 2 MoMs was significantly associated
with hydrocele (OR=1.88, 95% CI: 1.1-3.3).
Non-significant associations with elevated odds ratios included AFP ≥ 2 MoMs with two-
vessel cord (OR=1.73 95% CI: 0.5-5.9), hydrocele (OR=1.37, 95% CI: 0.4-5.3) and
undescended testicle (OR=1.72, 95% CI: 0.2-19.5); free β hCG ≥ 2 MoMs with pyloric
stenosis (OR=2.31, 95% CI: 0.7-7.4), multicystic dysplastic kidney (OR=2.73, 95% CI:
0.8-9.8), and undescended testes (OR=1.38, 95% CI: 0.6-3.3); hCG ≥ 2 MoMs with pyloric
stenosis (OR=1.48, 95% CI: 0.3-8.3); NT measurements of ≥ 2 MoMs with hydrocele
(OR=2.74, 95% CI: 1.0-7.4), two-vessel cord (OR=3.92, 95% CI: 0.2-64.1) and
undescended testicle (OR=3.84, 95% CI: 0.5-28.2); PAPP-A ≥ 2 MoMs with multicystic
dysplastic kidney (OR=1.91, 95% CI: 0.3-11.8); and. uE3≥ 2 MoMs was associated with
undescended testicles (OR=3.46, 95% CI: 0.2-56.6).
Non-significant associations with elevated odds ratios also included free β hCG levels of ≤
0.5 MoMs with multicystic dysplastic kidney (OR=1.49, 95% CI: 0.3-8.8); hCG ≤ 0.5
MoMs with undescended testicles (OR=2.67, 95% CI: 0.9-7.6); inhibin ≤ 0.5 MoMs with
two-vessel cord (OR=1.39, 95% CI: 0.4-4.6), pyloric stenosis (OR=7.88, 95% CI: 0.7-92.4),
multicystic dysplastic kidneys (OR=1.79, 95% CI: 0.1-21.5), and undescended testicles
(OR=1.38, 95% CI: 0.3-7.4); PAPP-A levels ≤ 0.5 MoMs with two vessel cord (OR=1.4,
95% CI: 0.4-4.7) and undescended testicles (OR=1.49, 95 CI: 0.4-5.0); and uE3 ≤ 0.5
MoMs with two-vessel cord (OR=7.78, 95% CI: 0.7-88.2) and undescended testicles
(OR=1.38, 95% CI: 0.3-7.4).
With regard to single gene disorder groups (Table 3b), no statistically significant
associations were found. Free β hCG ≥ 2 MoMs and inhibin ≥ 2 MoMs were associated
with skeletal dysplasias, with elevated odds ratios of 2.76 (95% CI: 0.5-15.1) and 2.56 (95%
CI: 0.3-18.9) respectively. High levels of inhibin and PAPP-A were also non-significantly
associated with the craniosynostosis syndromes (OR=1.77, 95% CI: 0.1-21.1 and 3.60, 95%
CI: 0.8-15.9, respectively).
DISCUSSION
Our results show that there are statistically significant associations between certain maternal
screening markers and specific anomalies. Use of the FASTER trial database allowed access
to one of the largest prospectively collected databases on maternal serum screen markers and
pediatric outcome. Collection of medical records was extensive and curated by experts in
genetics and neonatology. The database was meticulously reviewed and cleaned multiple
times, which allowed for accurate classification of common malformations and single gene
disorder groups.
Our results showed statistically significant associations between three common
malformations (multicystic dysplastic kidney, hydrocele, and 2-vessel cord) and three
commonly used maternal markers (hCG, inhibin and PAPP-A). Of these, multicystic
dysplastic kidney is the malformation with the most serious postnatal consequences. Of the
13 cases of multicystic dysplastic kideney, 4 of 13 had hCG ≥ 2.0 MoMs and 5 of 13 had
inhibin ≥ 2.0 MoMs. As prenatal ultrasound examination is only approximately 60%
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sensitive for abnormalities, identification of pregnancies with high levels of hCG and inhibin
could guide use of targeted renal sonographic studies or postnatal management that may
decrease morbidity and/ or mortality in multicystic dysplastic kidney. This information may
allow for enhanced prenatal counseling and monitoring of fetal renal function.
To date, relatively few studies have examined the association of maternal serum screening
markers with conditions other than aneuploidy and neural tube defects. In 2005 Celentano et
al. examined the possible association of elevated maternal serum hCG with fetal structural
abnormalities. In contrast to our study, their results showed that isolated hCG elevations did
not confer an increased risk for congenital anomalies other than those due to aneuploidy.
However, in this report, there were 8 major anomalies in the study group, and none of them
were multicystic dysplastic kidney.
Although the database used in this study was large, certain common anomalies and single
gene disorders are so rare, that not even a database of this size provided sufficient numbers
of outcome events to support precise statistical analysis. Thus, some of the associations with
large odds ratios, such as low inhibin and pyloric stenosis, or low estriol and 2-vessel cord,
failed to reach statistical significance. Despite this, some of the odds ratios observed were
very large, and for that reason, deserve mention.
Several previous studies have retrospectively analyzed maternal serum screening results
from cohorts of pregnant women whose children have certain single gene disorders. In 1998,
Tint et al., determined that an increased accumulation of fetal dehydrocholesterol in
amniotic fluid was an accurate predictor of Smith-Lemli-Opitz syndrome. These data led to
the observation that a low unconjugated maternal estriol serum level is associated with an
increased risk for Smith- Lemli-Opitz syndrome. Estriol is a downstream product of
cholesterol metabolism, which is disrupted in this syndrome (Bradley et al., 1999). In 1999,
Aitken reviewed serum screen results of 19 pregnancies that resulted in children with
Cornelia de Lange syndrome. A significant reduction in PAPP-A was seen in 18 of the 19
pregnancies, suggesting that in pregnancies with significantly low PAPP-A, there may be an
increased risk for Cornelia de Lange syndrome. Most recently, Begleiter (2007) suggested a
possible association between the 22q11.2 microdeletion syndrome and decreased levels of
maternal serum markers in three pregnancies, a finding that deserves further study. These
studies, in addition to the results presented here, suggest that software algorithms may be
developed that highlight the abnormal findings and prompt consideration of the anomaly or
the single gene disorder
The prospectively collected FASTER trial clinical database provided valuable pre- and post-
natal information that allowed us to study the relationship between common malformations,
single gene disorder groups and maternal screening results. Due to the limitations of
identifying large enough cohorts of patients with rare anomalies and single gene
malformations, we were unable to look at certain anomalies, such as congenital
diaphragmatic hernia, that might benefit from early detection and management. The
development of a large, international, prospective database would allow for further analysis
of maternal serum markers with certain anomalies and single gene conditions. Despite these
limitations this study has shown that certain patterns of routinely assayed maternal serum
markers, such as unexplained elevated hCG and inhibin levels, might suggest consideration
of a sonogram to rule out multicystic dysplastic kidney.
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Table 1
Demographic Information on pediatric outcome subset of FASTER Trial (n=35,496 pregnant women)
Characteristic Mean (SD) or %
Mean (SD) Maternal Age (years) 30 (5.8)
Mean (SD) Education (years) 14 (2.5)
Married (%) 78.7%
Mean (SD) Body Mass Index 25 (5.2)
Tobacco use during pregnancy (%) 4.7%
Illicit Drug use during pregnancy (%) (Cocaine, Marijuana, Heroin) 1%
Alcohol use during pregnancy (%) 2.1%
Medication use during pregnancy (%) 38%
Pregestational diabetes (%) 1%
Previous Live Birth (%) 54.7%
Previous Miscarriage (%) 26.1%
Previous Preterm Birth (%) 6.6%
Current Pregnancy result of ART *(%) 4.9%
ART= Assisted Reproductive Technology
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Table 2
Numbers of cases and controls for analysis of common congenital anomalies and single gene disorder groups
Congenital Anomaly Number of Cases Number of Matched Controls
Hydrocele 113 425
Undescended Testicle 41 148
Two Vessel Cord 39 147
Pyloric Stenosis 19 66
Multicystic Dysplastic Kidney 13 46
Single Gene Disorder Group
Craniosynostosis 14 50
Hemoglobinopathies 11 35
Skeletal Dysplasia /Connective Tissue Disorder 8 29
Metabolic Disorders 8 32
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Table 3b
Relationship between serum markers and single gene disorder groups
Serum Marker Craniosynostosis Hemoglobinopathies Skeletal Dysplasia Metabolic Disorders
AFP ≥ 2 MoM * 0.86 (0.1-8.7) 1.10 (0.1-12.3) *
fβhCG ≥ 2 MoM 1.14 (0.3-4.3) 0.75 (0.1-4.2) 2.76 (0.5-15.5) *
hCG ≥ 2 MoM 0.45 (0.1-4.0) 0.67 (0.1-6.5) 0.79 (0.1-8.2) *
Inhibin ≥ 2 MoM 1.77 (0.1-21.1) * 2.56 (0.3-18.9) *
NT ≥ 2 MoM * * * *
PAPP-A ≥ 2MoM 3.60 (0.8-15.9) 0.78 (0.1-7.8) 0.86 (0.1-9.0) 1.00 (0.1-10.4)
uE3 ≤ 0.5 MoM * * * *
All entries are odds ratios with 95% confidence intervals in parenthesis.
No values achieved statistical significance at p < 0.05.
*
Due to sample size limitations, odds ratios could not be estimated.
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